Scinai Gets Nasdaq Listing Extension
Ticker: SCNI · Form: 6-K · Filed: Jul 8, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: listing-compliance, extension, sec-filing
Related Tickers: SCNI
TL;DR
Nasdaq gives Scinai more time to fix listing issues - no delisting yet.
AI Summary
Scinai Immunotherapeutics Ltd. announced on July 3, 2024, that the Nasdaq Hearing Panel has granted an extension for the company to regain compliance with Nasdaq's continued listing requirements. This extension provides Scinai with additional time to meet the necessary criteria for remaining listed on the Nasdaq Stock Market.
Why It Matters
This extension gives Scinai Immunotherapeutics more time to address the issues that put its Nasdaq listing at risk, potentially avoiding delisting and maintaining investor confidence.
Risk Assessment
Risk Level: medium — The company is still in danger of being delisted if it cannot meet the Nasdaq's continued listing requirements within the granted extension period.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant
- Nasdaq Hearing Panel (company) — Granted the extension
- July 3, 2024 (date) — Date of press release
FAQ
What was the specific reason Scinai Immunotherapeutics needed an extension from the Nasdaq Hearing Panel?
The filing states the extension was granted to regain compliance with the continued listing requirements of the Nasdaq Stock Market.
When was the press release announcing this extension issued?
The press release was issued on July 3, 2024.
What is the former name of Scinai Immunotherapeutics Ltd.?
The former name of Scinai Immunotherapeutics Ltd. was BiondVax Pharmaceuticals Ltd.
What is the primary business of Scinai Immunotherapeutics Ltd. according to the filing?
The filing lists Scinai Immunotherapeutics Ltd. under the Standard Industrial Classification of Biological Products (No Diagnostic Substances) [2836].
What form is this filing?
This filing is a Form 6-K, Report of Foreign Private Issuer.
Filing Stats: 259 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2024-07-08 12:37:50
Filing Documents
- ea0209077-6k_scinai.htm (6-K) — 11KB
- ea020907701ex99-1_scinai.htm (EX-99.1) — 10KB
- 0001213900-24-059740.txt ( ) — 22KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: July 8, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2